Protein kinase C isozymes as therapeutic targets for treatment of human cancers.
作者信息
Fields Alan P, Murray Nicole R
机构信息
Mayo Clinic Comprehensive Cancer Center, Department of Cancer Biology, Jacksonville, FL, USA.
出版信息
Adv Enzyme Regul. 2008;48:166-78. doi: 10.1016/j.advenzreg.2007.11.014. Epub 2008 Mar 18.
Abstract
摘要
相似文献
1
Protein kinase C isozymes as therapeutic targets for treatment of human cancers.
Adv Enzyme Regul. 2008;48:166-78. doi: 10.1016/j.advenzreg.2007.11.014. Epub 2008 Mar 18.
2
Distinct protein kinase C isozymes signal mitogenesis and apoptosis in human colon cancer cells.
Gastroenterology. 1999 Oct;117(4):848-57. doi: 10.1016/s0016-5085(99)70343-4.
3
Protein kinase C isozymes in colon carcinogenesis: guilt by omission.
Gastroenterology. 2001 Jun;120(7):1868-72. doi: 10.1053/gast.2001.25287.
4
Selective involvement of protein kinase C isozymes in differentiation and neoplastic transformation.
Adv Cancer Res. 1994;64:159-209. doi: 10.1016/s0065-230x(08)60838-6.
5
Protein kinase C and tumor promoters.
Curr Opin Cell Biol. 1990 Apr;2(2):192-7. doi: 10.1016/0955-0674(90)90006-z.
6
Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma.
Cell Rep. 2020 Jan 21;30(3):771-782.e6. doi: 10.1016/j.celrep.2019.12.071.
7
Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis.
Mol Pathol. 1997 Jun;50(3):124-31. doi: 10.1136/mp.50.3.124.
8
Protein kinase C iota: human oncogene, prognostic marker and therapeutic target.
Pharmacol Res. 2007 Jun;55(6):487-97. doi: 10.1016/j.phrs.2007.04.015. Epub 2007 May 5.
9
Ultraviolet radiation-induced melanogenesis in human melanocytes. Effects of modulating protein kinase C.
J Cell Sci. 1994 Sep;107 ( Pt 9):2591-7. doi: 10.1242/jcs.107.9.2591.
10
Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer.
Cancer Res. 2005 Oct 1;65(19):8905-11. doi: 10.1158/0008-5472.CAN-05-2372.
引用本文的文献
1
Impact of peptide permeation enhancer on tight junctions opening cellular mechanisms.
Biochem Biophys Rep. 2022 Oct 27;32:101375. doi: 10.1016/j.bbrep.2022.101375. eCollection 2022 Dec.
2
Structure-activity relationship of a peptide permeation enhancer.
Tissue Barriers. 2023 Jan 2;11(1):2060692. doi: 10.1080/21688370.2022.2060692. Epub 2022 Apr 3.
3
Regulates Autophagy and Pancreatic Tumorigenesis in Mice.
Cancers (Basel). 2022 Feb 4;14(3):796. doi: 10.3390/cancers14030796.
4
Clinical significance of atypical protein kinase C (PKCι and PKCζ) and its relationship with yes-associated protein in lung adenocarcinoma.
BMC Cancer. 2019 Aug 14;19(1):804. doi: 10.1186/s12885-019-5992-7.
5
The roles of PKCs in regulating autophagy.
J Cancer Res Clin Oncol. 2018 Dec;144(12):2303-2311. doi: 10.1007/s00432-018-2731-4. Epub 2018 Aug 16.
6
Downregulation of PKCζ/Pard3/Pard6b is responsible for lung adenocarcinoma cell EMT and invasion.
Cell Signal. 2017 Oct;38:49-59. doi: 10.1016/j.cellsig.2017.06.016. Epub 2017 Jun 24.
7
Inhibition of PKCα reduces the ability of migration of kidney cancer cells but has no impact on cell apoptosis.
Exp Ther Med. 2017 May;13(5):2473-2479. doi: 10.3892/etm.2017.4258. Epub 2017 Mar 23.
8
PKCι regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.
Oncogene. 2017 Jan 26;36(4):534-545. doi: 10.1038/onc.2016.224. Epub 2016 Jun 20.
9
The chromosome 3q26 OncCassette: A multigenic driver of human cancer.
Adv Biol Regul. 2016 Jan;60:47-63. doi: 10.1016/j.jbior.2015.10.009. Epub 2015 Dec 23.
10
Protein kinase Cδ promotes proliferation and induces malignant transformation in skeletal muscle.
J Cell Mol Med. 2015 Feb;19(2):396-407. doi: 10.1111/jcmm.12452. Epub 2014 Oct 6.
本文引用的文献
1
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
J Clin Oncol. 2007 May 1;25(13):1741-6. doi: 10.1200/JCO.2006.09.3146. Epub 2007 Mar 26.
2
Protein kinase C-mediated down-regulation of cyclin D1 involves activation of the translational repressor 4E-BP1 via a phosphoinositide 3-kinase/Akt-independent, protein phosphatase 2A-dependent mechanism in intestinal epithelial cells.
J Biol Chem. 2007 May 11;282(19):14213-25. doi: 10.1074/jbc.M610513200. Epub 2007 Mar 13.
3
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
J Clin Oncol. 2006 Sep 1;24(25):4092-9. doi: 10.1200/JCO.2005.05.3447.
4
Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota.
J Biol Chem. 2006 Sep 22;281(38):28450-9. doi: 10.1074/jbc.M606054200. Epub 2006 Jul 22.
5
Protein kinase C alpha but not PKCzeta suppresses intestinal tumor formation in ApcMin/+ mice.
Cancer Res. 2006 Jul 15;66(14):6955-63. doi: 10.1158/0008-5472.CAN-06-0268.
6
Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma.
Cancer Res. 2006 May 1;66(9):4627-35. doi: 10.1158/0008-5472.CAN-05-4527.
7
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
J Clin Oncol. 2006 Mar 20;24(9):1428-34. doi: 10.1200/JCO.2005.04.3299.
8
A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.
Cancer Res. 2006 Feb 1;66(3):1767-74. doi: 10.1158/0008-5472.CAN-05-3405.
9
Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer.
Cancer Res. 2005 Oct 1;65(19):8905-11. doi: 10.1158/0008-5472.CAN-05-2372.
10
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Cancer Res. 2005 Aug 15;65(16):7462-9. doi: 10.1158/0008-5472.CAN-05-0071.
Zotero 插件